[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"brand-akesobio":3},{"head":4,"company":39,"invest":44,"children":45,"shops":46,"category":47,"sameIndustry":5,"rid":6},{"createTime":5,"updateTime":5,"createBy":5,"updateBy":5,"brandId":6,"brandLogo":7,"brandImage":5,"brandName":8,"webName":9,"balias":5,"enterId":10,"mainindustry":11,"industry":5,"brandType":5,"brandHonor":5,"brandTel":5,"establishdate":12,"brandBirth":13,"cityarea":5,"brandWebsite":5,"brandSobp":5,"brandVisit":5,"totalVisits":14,"status":15,"isDeleted":15,"comment":5,"remark":5,"logoExistStatus":16,"imageExistStatus":16,"industryId":5,"industryRanking":5,"score":5,"enterName":17,"mallShopList":18,"brandSummary":19,"likes":5,"unlikes":5,"follow":5,"pagetitle":20,"pagekeywords":21,"pagedesc":22,"brandContent":23,"province":5,"city":5,"area":5,"detailaddress":24,"unifiedscc":25,"enterType":26,"enterLegalperson":27,"enterStablishdate":28,"regauthority":29,"licenseValidity":30,"approvaldate":31,"regcapital":32,"incapital":33,"businessscope":34,"ownBrand":5,"enterTelphone":35,"enterWebsite":36,"business":37,"enterQq":5,"enterMail":38,"bindUser":5,"enterMployeenum":5,"regcapitalunit":5,"abnormal":5,"yeartax":5,"regtrademark":5},null,"90365","\u002Fprofile\u002Fupload\u002F2025\u002F01\u002F25\u002F8b1c6a520305ca7efc6a6dfb897cc5bf.gif","康方Akesobio","akesobio",88975,10006,"2012年","中山市",395,0,"1","中山康方生物医药有限公司",[],"康方生物成立于2012年，是一家集研究、开发、生产及商业化全球病人可负担的创新抗体新药于一体的生物制药公司，于2020年在港交所上市（股票代码：9926.HK），建立了以Tetrabody双特异性抗体开发技术、抗体偶联（ADC）技术平台、mRNA技术平台及细胞治疗技术为核心的研发创新体系，旗下拥有50个以上用于治疗肿瘤、自身免疫、炎症、代谢疾病等重大疾病的创新候选药物。","康方Akesobio简介-康方医药用品-品牌之家","康方Akesobio品牌介绍,康方医药用品好不好,康方怎么样,康方,中山康方生物医药有限公司","康方Akesobio品牌简介，品牌之家为你介绍中山康方生物医药有限公司旗下康方Akesobio品牌信息，包括品牌介绍、联系方式、主营产品、最新评论、点赞数量等，告诉你康方医药用品怎么样，致力于帮助你了解康方Akesobio真实有效的品牌相关信息。","康方生物（港交所股票代码：9926.HK）是一家致力于研究、开发、生产及商业化全球病人可负担的创新抗体新药的生物制药公司。公司于2020年4月24日正式在香港联合交易所有限公司主板挂牌上市。\n\n自成立以来，公司建立了端对端的药物开发平台（ACE平台）和体系，涵盖了一体化的药物发现和开发功能，包括靶点验证、抗体发现与开发、CMC生产工艺开发和符合GMP标准的规模化生产。公司也成功开发了双特异抗体药物开发技术（Tetrabody技术）。\n\n公司目前拥有20个以上用于治疗肿瘤、自身免疫、炎症、代谢疾病等重大疾病的创新药物产品管线，9个品种进入临床研究，包括两个国际首创的双特异性抗体新药（PD-1\u002FCTLA-4以及PD-1\u002FVEGF）。康方生物期望通过有效及突破性的研发创新开发新药，成为全球领先的生物制药企业。\n\n在肿瘤治疗领域，康方生物处于开发阶段后期的产品包括一款PD-1\u002FCTLA-4双特异性抗体新药（AK104），一款PD-1单克隆抗体派安普利（AK105）以及一款潜在的全首创PD-1\u002FVEGF双特异性抗体（AK112）。在自身免疫性疾病领域，公司已经开发出中国生物制药公司里丰富的创新产品管线之一，产品包括一款L-12\u002FIL-23单克隆\n\n抗体（AK101），一款L-17单克隆抗体（AK111），一款已在澳洲获得IND批准的IL-4R抗体（AK120），以及一款处于IND研究阶段的IL-1 beta抗体（AK114）。","中山市火炬开发区神农路6号","91442000590136839L","有限责任公司(港澳台投资、非独资)","XIA YU","2012-03-19","广东省中山市工商行政管理局","2012-03-19 至 2042-03-15","2022-05-27","500,000万(元)","451,305.3万(元)","许可项目：药品生产；药品批发；药品进出口。（依法须经批准的项目，经相关部门批准后方可开展经营活动，具体经营项目以相关部门批准文件或许可证件为准）一般项目：医学研究和试验发展；技术服务、技术开发、技术咨询、技术交流、技术转让、技术推广；化工产品销售（不含许可类化工产品）；以自有资金从事投资活动；货物进出口；技术进出口（国家禁止或涉及行政审批的货物和技术进出口除外）（上述经营范围涉及货物或技术进出口。）（上述经营范围不含中药饮片的蒸、炒、炙、煅等炮制技术的应用及中成药保密处方产品的生产，不含人体干细胞、基因诊断与治疗技术的开发和应用）。（以上项目不涉及外商投资准入特别管理措施）（除依法须经批准的项目外，凭营业执照依法自主开展经营活动）","0760-89873998","www.akesobio.com","医药制造业","li02.huang@akesobio.com",{"enterId":40,"enterName":17,"province":5,"city":5,"area":5,"detailaddress":24,"unifiedscc":25,"enterType":26,"enterLegalperson":27,"enterStablishdate":28,"regauthority":29,"licenseValidity":30,"approvaldate":31,"regcapital":32,"incapital":33,"businessscope":34,"ownBrand":5,"enterTelphone":35,"enterWebsite":36,"business":37,"performance":41,"socialSecurity":42,"registrationNumber":43,"enterQq":5,"enterMail":38,"bindUser":5,"enterMployeenum":5,"regcapitalunit":5,"abnormal":5,"yeartax":5,"status":15,"regtrademark":5,"remark":5},"88975","开业","632人","442000400041224",{"createTime":5,"updateTime":5,"createBy":5,"updateBy":5,"id":5,"brandId":5,"brandName":5,"busmodel":5,"franchiseFund":5,"totalStores":5,"devmodel":5,"franchiseIndustry":5,"investmenttel":5,"suitablePeople":5,"state":5},[],[],[48],{"createTime":49,"updateTime":50,"createBy":5,"updateBy":5,"industryId":51,"webId":5,"industryName":52,"industryAlias":5,"industryIcon":5,"industryTrans":53,"pageTitle":54,"pageDesc":55,"pageKeywords":56,"mainTitle":57,"pageSubtitle":58,"indSummary":59,"industryLevel":60,"parentId":61,"parentName":5,"sortOrder":62,"status":15,"classifyVisit":5,"totalVisits":63,"searchName":5,"starLevel":5,"limit":5},"2000-01-01 00:00:00","2026-06-16 16:50:00","10006","生物科技","\u002Fprofile\u002Fupload\u002F2023\u002F11\u002F08\u002F19f46e89d8cd077b73c7adb33bb2b59f.png","生物科技公司十大排行榜-国内知名生物科技公司有哪些-ZGALL品牌榜","2026年十大生物科技公司排行榜最新发布，生物科技公司十大排行榜前十名有中国生物、中国生物制药、百济神州、恒瑞、豪森药业、百利天恒、康方、复星医药、石药、信达。生物科技十大品牌排行榜由品牌研究部门收集整理大数据分析研究得出，帮助你了解中国生物科技公司有哪些。","生物科技公司排名前十有哪些,中国生物科技公司排名前十,生物科技有限公司排名,中国生物科技公司排名,全国生物科技公司排名","生物科技品牌排行榜","2026生物科技公司，生物制药公司排行榜，国内生物医药科技公司有哪些","生物科技哪个好？品牌TOP榜权威发布2026年生物科技名录；居前十的有：中国生物CNBG、中国生物制药、百济神州BeiGene、恒瑞医药、豪森药业、百利天恒、康方Akesobio、复星医药、石药CSPC、信达生物Innovent等，【行业品牌名录】基于大数据与人工智能技术，整合300+国际权威榜单及企业申报数据，通过算法分析市场占有率、创新力等12项指标，并解析超百万条舆情信息，采用加权模型（算法60%+专家30%+用户10%）生成动态排名。数据月度更新，申报需通过ISO认证审核，排名不分先后，仅供参考。",3,1411,99,589]